Business Context and Reporting Period
This Form 8-K is a Current Report filed by Bristol-Myers Squibb Company on January 10, 2022. The filing serves as a Regulation FD disclosure to announce the posting of an investor presentation on the company's website.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a notice of an external presentation rather than a financial statement itself.
Material Changes
No material changes to financial performance or operations are detailed within the text of this filing. The primary event reported is the release of an investor presentation dated January 10, 2022.
Guidance, Outlook, and Risks
The filing references an attached investor presentation (Exhibit 99.1) which likely contains management commentary, outlook, and guidance. However, the text of the 8-K explicitly states that the information in the presentation is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. No specific risks or contingencies are described in this document.
Key Facts for Investor Verification
- Verify the contents of the investor presentation attached as Exhibit 99.1 for actual financial data and guidance.
- Note that the presentation materials are not legally "filed" with the SEC and are not subject to the liabilities of Section 18 of the Exchange Act.
- Confirm the trading symbols for the company's securities listed in the filing: Common Stock (BMY), 1.000% Notes due 2025 (BMY25), 1.750% Notes due 2035 (BMY35), and Celgene Contingent Value Rights (CELG RT).